



25th February 2026

To

The Secretary

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai 400 001

Scrip Code: 500674

The Secretary

The National Stock Exchange of India Limited Exchange

Plaza, C-1, Block G,

Bandra-Kurla Complex, Bandra (E)

Mumbai 400 051

Symbol: SANOFI

Sub: Outcome of the Board Meeting of the Company held on Wednesday, 25th February 2026

Dear Sirs/Madam,

We refer to our intimation dated 19th February 2026 informing about our Board Meeting scheduled for today. In this regard, we wish to inform that the Board of Directors at its meeting held today i.e., Wednesday, 25th February 2026, *inter-alia*:

- 1. Considered and Approved the Audited Financial Results and Statements** for the Quarter and Financial Year ended 31st December 2025.

Accordingly, we enclose a copy of the Auditor's Report and Audited Financial Results of the Company for the Financial Year ended 31st December 2025, along with Statement of Assets and Liabilities as on that date and Statement of Cashflows for the year ended 31st December 2025, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for records.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid financial results will also be available on the Company's website on [Financial results - Sanofi India](#)

Further, pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, M/s Price Waterhouse & Co. Chartered Accountants LLP have issued the Audit Report with unmodified opinion for the Financial Year ended 31st December 2025.

- 2. Considered and recommended** a final dividend of ₹ 48 per equity share of the face value of ₹10 each for the Financial Year ended 31st December 2025, subject to the approval of Shareholders at the ensuing 70th Annual General Meeting. The final dividend is in addition to the interim dividend of ₹ 75 per equity share of the face value of ₹ 10 each declared on 29th October 2025. The total dividend for the year 2025 will be ₹ 123 per equity share of the face value of ₹ 10 each.



3. Change in Directors - Pursuant to the Regulation 30 of the SEBI Listing Regulations, 2015, we wish to inform as follows :

- Upon the recommendation of the Nomination and Remuneration Committee and subject to approval of the Shareholders, the Board of Directors have approved the appointment of Mrs. Rajani Kesari (DIN: 02384170) as an Additional Director and Independent Director of the Company for a term of 5 (Five) years with effect from 01st April 2026. She shall hold office as an Additional Director up to the date of the ensuing 70th Annual General Meeting (AGM).
- Mr. Rodolfo Hrosz (DIN: 09609832) has tendered his resignation from his position as the Non - Executive Director of the Company, with effect from the closure of business hours on 28th February 2026 owing to other pre-occupation and commitments. Mr. Hrosz has confirmed to the Company that there are no other material reasons for his resignation other than those which are mentioned above. A copy of his resignation letter is enclosed.

The Board of Directors have noted his resignation and place on record their immense appreciation for Mr. Rodolfo Hrosz's valuable contribution during his tenure with the Company.

- Upon the recommendation of the Nomination and Remuneration Committee and subject to approval of the Shareholders, the Board of Directors have approved the appointment of Ms. Sudipta Chakraborty (DIN: 07166912) as an Additional Director and Whole-time Director of the Company for a term of 3 (Three) years with effect from 01st March 2026. Accordingly, Ms. Sudipta Chakraborty shall be designated as a Key Managerial Personnel and a Senior Management Personnel of the Company, effective from the said date. She shall hold office as an Additional Director up to the date of the ensuing 70th Annual General Meeting.

The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 and Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/2018 19 and the National Stock Exchange of India Ltd with ref. no. NSE/CML/2018/24, dated 20th June 2018 is enclosed as Annexure I to this letter.

The meeting of Board of Directors commenced at 2:00 p.m. and concluded at 5:30 p.m.

Please take the above information on record.

Thanking you,
Yours faithfully

For **Sanofi India Limited**

Haresh Vala
Company Secretary and Compliance Officer
Membership No.: A18246

Encl: a/a

Information as required under Regulation 30 read with Schedule III - Para A of Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

1. Appointment of Mrs. Rajani Kesari (DIN: 02384170) as an Additional Director and Independent Director of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Mrs. Rajani Kesari (DIN: 02384170) as an Additional Director and Independent Director of the Company, subject to the approval of the shareholders.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment;	Appointed as an Additional Director of the Company with effect from 01 st April 2026. Appointed as the Independent Director of the Company for a term of 5 (Five) years with effect from 01 st April 2026.
3.	Brief profile (in case of appointment)	<p>Mrs. Rajani Kesari is a commerce graduate, Chartered Accountant, Cost Accountant and Certified Public Accountant from the US. In her last assignment, she was the Chief Financial Officer (CFO) of Nayara Energy Limited. Prior to Nayara, she was the CFO for Holcim India, handling finance for listed entities of Ambuja Cements and ACC Limited. Mrs. Kesari has diverse experience with global profile in strategic planning, business partnering, M & A, internal audit, taxation and investor relations. She has also played a very meaningful role in driving business impact both in India and overseas.</p> <p>Mrs. Kesari has skills in Business Partnering, M&A and subsequent integrations, Simplification programs for cost efficiencies, Internal Audit and Internal Controls, Global Tax, Treasury, Shared Services implementation and leadership and Accounting. She has worked in different geographies leading teams from diverse cultures and has proven track record in identifying and developing talent and creating an engaged team. Mrs. Rajani Kesari has professional experience in different industries and business models working in Energy Management, Pharmaceutical and Building materials industries.</p>

4.	Disclosure of relationships between directors (in case of appointment of a director).	Mrs. Rajani Kesari is not related to any of the Directors of the Company personally, financially or otherwise and is not debarred or disqualified from being appointed as director of any company by SEBI / Ministry of Corporate Affairs or any such statutory authority.
5.	Information pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24 ('Circulars')	Mrs. Rajani Kesari is not debarred or disqualified from being appointed or continuing as director of any company by SEBI / Ministry of Corporate Affairs or any such authority as required under the Circulars. Signed disclosure is enclosed herewith.

2. Resignation of Mr. Rodolfo Hrosz (DIN: 09609832) as the Non - Executive Director of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Resignation of Mr. Rodolfo Hrosz (DIN: 09609832) as the Non - Executive Director of the Company, owing to other pre-occupation and commitments.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment;	With effect from the close of business hours on 28 th February 2026.
3.	Brief profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
5.	Information pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24 ('Circulars')	Not Applicable

3. Appointment of Ms. Sudipta Chakraborty (DIN: 07166912) as an Additional Director and Whole-time Director of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Ms. Sudipta Chakraborty (DIN: 07166912) as an Additional Director and Whole-time Director of the Company, subject to the approval of the shareholders.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment;	<p>Appointed as an Additional Director of the Company with effect from 01st March 2026.</p> <p>Appointed as the Whole-time Director of the Company for a term of 3 (Three) years with effect from 01st March 2026.</p>
3.	Brief profile (in case of appointment)	<p>Ms. Sudipta Chakraborty brings over two decades of multifaceted legal experience, having built scaled and led high-performing and cross-cultural, legal, compliance, and taxation teams across geographies, with a focus on APAC and China region. Her professional journey spans leadership roles across jurisdictions and various sectors and in her last role she was Vice President- Group Legal & Compliance at the Aditya Birla Group and also a member of the Group’s Global Legal Leadership Team. Ms. Chakraborty has a proven track record of driving impact with a strong enterprise leadership mindset to legal, compliance and regulatory strategy, risk management, and innovation enablement. Under her leadership, her teams have been recognized as true competitive advantage for the organization.</p> <p>Ms. Chakraborty specializes in Mergers & Acquisitions, Corporate Restructuring and Antitrust laws, Corporate Governance and Compliance, Intellectual Property laws, Pharmaceutical and FMCG sector specific laws, Privacy and Technology laws, Ethics, Business Integrity and Investigations, Labour laws and Taxation laws.</p> <p>At Sanofi India Limited, Ms. Chakraborty leads the legal function with a strong focus on strengthening compliance, governance frameworks, regulatory readiness, and intellectual property strategy, ensuring alignment with the company’s mission of delivering innovative healthcare solutions responsibly and ethically, amid evolving healthcare regulations and rapid industry transformation.</p>

		She is a 2005 graduate of the National Law School of India University (NLSIU), Bengaluru and holds a B.A LLB (Hons) degree.
4.	Disclosure of relationships between directors (in case of appointment of a director).	Ms. Sudipta Chakraborty is not related to any of the Directors of the Company personally, financially or otherwise and is not debarred or disqualified from being appointed as director of any company by SEBI / Ministry of Corporate Affairs or any such statutory authority.
5.	Information pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24 ('Circulars')	Ms. Sudipta Chakraborty is not debarred or disqualified from being appointed or continuing as director of any company by SEBI / Ministry of Corporate Affairs or any such authority as required under the Circulars. Signed disclosure is enclosed herewith.


To,
The Board of Directors
Sanofi India Limited
Sanofi House, C.T.S-117 B
L&T Business Park, Saki Vihar Road,
Powai, Mumbai, Maharashtra, India, 400072

Sub: Non-Debarment Confirmation

I, **Rajani Kesari**, proposed Independent Director of Sanofi India Limited, hereby confirm that I have not been debarred from being appointed or continue as a Director of the Company by the Ministry of Corporate Affairs (MCA), Securities Exchange Board of India (SEBI), or any other statutory authority.

I shall inform the Company immediately upon any change in the above declaration.

Yours faithfully,



Name : Rajani Kesari

Designation: Proposed Independent Director

DIN: 02384170

Date: 24th February 2026

Place: Mumbai, India

24 February, 2026

The Board of Directors
Sanofi India Limited
Sanofi House, CTS No.117-B
L&T Business Park , Saki Vihar Road, Powai
Mumbai 400 072, India

Dear Chairman & Board of Directors,

Subject: Resignation as Non-Executive Director of the Company

Due to my other pre-occupation and commitments, I hereby submit my resignation as a Non-Executive Director of Sanofi India Limited with effect from the close of business hours on 28 February, 2026.


I confirm that there is no other material reason other than the one that is mentioned above for my resignation.

I take this opportunity to thank all the Board Members for the guidance and support during my tenure on the Board of the Company.

I request you to complete all the formalities with regard to my resignation including filing of required forms with the Ministry of Corporate Affairs and intimating to the other relevant authorities as may be required.

I wish the Company success in times to come.

Yours sincerely,



Rodolfo Hrosz
DIN : 09609832

To,
The Board of Directors
Sanofi India Limited
Sanofi House, C.T.S-117 B
L&T Business Park, Saki Vihar Road,
Powai, Mumbai, Maharashtra, India, 400072

Sub: Non-Debarment Confirmation

I, **Sudipta Chakraborty**, hereby confirm that I have not been debarred from being appointed or continue as a Director of the Company by the Ministry of Corporate Affairs (MCA), Securities Exchange Board of India (SEBI), or any other statutory authority.

I shall inform the Company immediately upon any change in the above declaration.

Yours faithfully,



Name: Sudipta Chakraborty
DIN: 07166912
Date: 24th February 2026
Place: Mumbai

Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Sanofi India Limited

Report on the Audit of Financial Results

Opinion

1. We have audited the accompanying annual financial results of Sanofi India Limited (the "Company") for the year ended December 31, 2025 and the statement of assets and liabilities as on that date and the statement of cash flows for the year ended on that date (the "financial results"), attached herewith, which are included in the accompanying 'Statement of Audited Financial Results for the year ended December 31, 2025' (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations') which has been initialled by us for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us, the financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended December 31, 2025 and the statement of assets and liabilities and the statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Price Waterhouse & Co Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West)
Mumbai - 400 028
T: +91 (22) 66697508

Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Sanofi India Limited

Report on the Financial Results

Page 2 of 3

Board of Directors' Responsibilities for the Financial Results

4. These financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the statement of assets and liabilities and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.
5. In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

7. Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Sanofi India Limited

Report on the Financial Results

Page 3 of 3

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Financial Results include the results for the quarter ended December 31, 2025 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Price Waterhouse & Co Chartered Accountants LLP

Firm Registration Number: 304026E/ E-300009

ARUNKUMA Digitally signed by
ARUNKUMAR RAMDAS

R RAMDAS Date: 2026.02.25
18:06:50 +05'30'

Arunkumar Ramdas

Partner

Membership Number: 112433

UDIN: 26112433EPODPE8931

Place: Mumbai

Date: February 25, 2026

SANOFI INDIA LIMITED

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.
Corporate Identity Number: L24239MH1956PLC009794
Tel no: (91-22) 28032000 Fax No: (91-22) 28032846
Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025

₹ in Million

Particulars	Quarter ended 31.12.2025 (Unaudited) (Refer note 9)	Quarter ended 30.09.2025 (Unaudited)	Quarter ended 31.12.2024 (Unaudited) (Refer note 9)	Year ended 31.12.2025 (Audited)	Year ended 31.12.2024 (Audited) (Refer Note 3)
Continuing Operations					
1. Revenue from Operations	4,198	4,754	5,149	18,374	20,132
2. Other Income	28	49	59	197	165
3. Total Income (1+2)	4,226	4,803	5,208	18,571	20,297
4. Expenses					
(a) Cost of Materials Consumed	553	533	1,027	2,464	3,548
(b) Purchases of stock-in-trade	1,245	2,698	2,385	5,140	5,643
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	283	(832)	(914)	1,368	602
(d) Employee benefits expense	447	419	538	1,853	2,402
(e) Finance costs	6	4	4	17	15
(f) Depreciation and amortisation expense	95	91	96	373	367
(g) Other expenses	767	594	930	2,636	3,029
Total Expenses	3,396	3,507	4,066	13,851	15,606
5. Profit before exceptional items and tax from continuing operations (3-4)	830	1,296	1,142	4,720	4,691
6. Exceptional items (net) (Refer note 4)	-	(273)	80	(273)	(377)
7. Profit before tax from continuing operations (5+6)	830	1,023	1,222	4,447	4,314
8. Income tax expense from continuing operations					
Current Tax	210	312	279	1,229	1,258
Deferred Tax	3	(49)	30	(49)	(81)
9. Profit for the period /year from continuing operations (7-8)	617	760	913	3,267	3,137
10. Profit before tax from discontinued operations	-	-	-	-	1,312
11. Tax expense from discontinued operations	-	-	-	-	314
12. Profit for the period /year from discontinued operations (10-11)	-	-	-	-	998
13. Profit for the period /year (9+12)	617	760	913	3,267	4,135
14. Other comprehensive income (OCI) (Net of Tax) from continuing operations	17	-	72	17	72
15. Other comprehensive income (OCI) (Net of Tax) from discontinued operations	-	-	-	-	-
16. Total Other comprehensive income (OCI) (Net of Tax) (14+15)	17	-	72	17	72
17. Total comprehensive income for the period/year (13+16)	634	760	985	3,284	4,207
18. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230
19. Other equity	-	-	-	7,262	8,376
20. Basic and diluted earnings per share (not annualised) (in ₹)					
Continuing Operations	26.79	32.99	39.64	141.85	136.21
Discontinued Operations	-	-	-	-	43.33
Continuing and Discontinued Operations	26.79	32.99	39.64	141.85	179.54

**ARUNKUMAR
RAMDAS**

Digitally signed by ARUNKUMAR
RAMDAS
Date: 2026.02.25 18:07:23 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 25, 2026

**Deepak
Arora** Digitally signed
by Deepak Arora
Date: 2026.02.25
17:46:58 +05'30'

SANOFI INDIA LIMITED
STATEMENT OF ASSETS AND LIABILITIES

₹ in Million

	As at December 31, 2025 Audited	As at December 31, 2024 Audited
ASSETS		
Non-current assets		
Property, plant and equipment	2,493	2,558
Capital work in progress	116	181
Right-of-use assets	541	554
Intangible assets	7	13
Financial assets		
Other financial assets	68	127
Income tax assets (net)	1,212	1,375
Deferred tax assets (net)	44	1
Other non-current Assets	61	41
Total non-current assets	4,542	4,850
Current assets		
Inventories	3,116	4,998
Financial assets		
(i) Trade receivables	1,767	2,300
(ii) Cash and cash equivalents	2,629	2,838
(iii) Bank Balances other than (ii) above	120	110
(iv) Loans	9	10
(v) Other financial Assets	28	452
Other current assets	337	560
Total current assets	8,006	11,268
TOTAL ASSETS	12,548	16,118
EQUITY AND LIABILITIES		
Equity		
Equity share capital	230	230
Other equity		
Reserves and surplus	7,262	8,376
Total equity	7,492	8,606
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Lease liabilities	137	140
Provisions - employee benefit obligations	5	7
Total non-current liabilities	142	147
Current liabilities		
Financial liabilities		
(i) Lease liabilities	41	53
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	100	221
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,840	3,842
(iii) Other financial liabilities	610	818
Provisions - others	1,135	1,185
Provisions - employee benefit obligations	198	239
Current tax liabilities (net)	957	959
Other current liabilities	33	48
Total current liabilities	4,914	7,365
Total liabilities	5,056	7,512
TOTAL EQUITY AND LIABILITIES	12,548	16,118

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 25, 2026

ARUNKUMAR RAMDAS
Digitally signed by
ARUNKUMAR RAMDAS
Date: 2026.02.25
18:07:43 +05'30'

Deepak Arora
Digitally signed
by Deepak Arora
Date: 2026.02.25
17:47:27 +05'30'

SANOFI INDIA LIMITED
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2025

₹ in Million

Particulars	Year ended December 31, 2025 Audited	Year ended December 31, 2024 Audited (Refer note 3)
Cash flow from operating activities		
Profit before tax :		
Continuing Operations	4,447	4,314
Discontinued Operations	-	1,312
Profit before income tax including Discontinued Operations	4,447	5,626
Adjustment for Continuing and Discontinued Operations :		
Depreciation and amortization expenses	373	382
Unrealised exchange (gain) / loss (net)	14	6
(Gain) on sale of property, plant and equipment	(1)	(5)
Gain on termination/retirement of lease (net)	(12)	-
Finance costs	17	15
Interest income	(140)	(166)
Share based payment (net)	24	12
Provision for bad and doubtful debts (net)	11	2
Provision for doubtful advances and deposits (net)	2	5
Operating profit before working capital changes	4,735	5,877
Adjustments for (increase) / decrease in operating assets		
Non-current financial assets	57	(21)
Other non-current assets	1	(7)
Inventories	1,882	687
Trade receivables	531	(1,270)
Current financial assets, loans and other bank balances	415	(357)
Other current assets	223	(898)
Adjustments for increase / (decrease) in operating liabilities		
Provisions - employee benefit obligations	(20)	156
Trade payables	(2,149)	1,662
Current financial liabilities	(159)	(165)
Other current liabilities, loans and provisions - others	(65)	(73)
Cash generated from operations	5,451	5,591
Taxes paid (Net of refunds)	(1,068)	(974)
Net cash inflow from operating activities (A)	4,383	4,617
Cash flow from Investing activities		
Sale proceeds of property, plant and equipment	4	6
Interest received	140	166
Purchase of property, plant and equipment and Intangible assets including Capital work-in-progress	(257)	(364)
Net cash outflow for investing activities (B)	(113)	(192)
Cash flow from financing activities		
Principal elements of lease payments	(43)	(63)
Interest paid for leases	(14)	(15)
Dividend paid	(4,422)	(3,846)
Net cash outflow for financing activities (C)	(4,479)	(3,924)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	(209)	501
Effect of Exchange differences on cash and cash equivalents held in foreign currency	*	*
Cash and Cash Equivalents at the beginning of the year	2,838	3,929
Less : Cash Transferred pursuant to demerger (Refer Note 3)	-	(1,592)
Cash and Cash Equivalents at the end of the year	2,629	2,838
Non- cash financing and investing activities (D)		
Acquisition of Right-of-use assets	131	66
Components of Cash and Cash Equivalents		
Cash and Cash Equivalents	2,629	2,838

* denotes figure less than a million.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 25, 2026

ARUNKUMAR RAMDAS Digitally signed by
ARUNKUMAR RAMDAS
Date: 2026.02.25
18:08:09 +05'30'

Deepak Arora Digitally signed
by Deepak Arora
Date: 2026.02.25
17:47:56 +05'30'

Notes:

1. The above Results have been reviewed by the Audit Committee at its meeting held on February 24, 2026 and approved by the Board of Directors of the Company at its Meeting held on February 25, 2026.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. The Company demerged its Consumer Healthcare business effective June 1, 2024, after obtaining approval of the NCLT. Consequently, financial results for the Consumer Healthcare business are presented as discontinued operations for the year ended December 31, 2024.
4. Exceptional items relate to personnel separation costs of ₹273 million for the year ended December 31, 2025. Comparative amount was ₹377 million for the year ended December 31, 2024, net of ₹80 million reversal in the quarter ended December 31, 2024.
5. On November 21, 2025, the Government of India notified the four consolidated Labour Codes, replacing several existing labour laws. Based on the draft rules and the guidance currently available, the Company has evaluated the impact of the revised definition of wages on its employee benefit obligations in accordance with Ind AS 19.

Following this assessment and the related actuarial valuation, the incremental impact arising from the implementation of the Labour Codes of ₹ 58 million has been recognised under Employee Benefits Expense in the current year. The Company will assess the final applicable Central and State Rules upon official notification and account for any differential financial impact, in the reporting period in which such Rules, or any pertinent clarifications thereto, are effective.

6. The Company has a single business segment namely 'Pharmaceutical Business'.
7. Along with the interim dividend of ₹ 75 per equity share of ₹ 10, declared on October 29, 2025, the Board has recommended the final Dividend at ₹ 48 per equity share of ₹ 10 for the year ended December 31, 2025, bringing the total dividend for the year to Rs. 123 per equity share. The final dividend will be paid after approval of shareholders at ensuing Annual General Meeting of the Company.
8. For the year ended December 31, 2025, export sales were lower by ₹ 1,481 million (For Q4 2025- ₹ 530 million) mainly due to the anticipated cessation of contract with Zentiva.
9. The figures for the quarter ended December 31, 2025 and December 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures upto third quarter of the financial year.

ARUNKUMAR RAMDAS Digitally signed by
ARUNKUMAR RAMDAS
Date: 2026.02.25
18:08:44 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated February 25, 2026

SANOFI INDIA LIMITED

Deepak Arora Digitally signed
by Deepak Arora
Date: 2026.02.25
17:48:31 +05'30'

DEEPAK ARORA
MANAGING DIRECTOR
DIN: 07495638

February 25, 2026